NeuroDerm
Rehovot, Israel· Est.
NeuroDerm creates a continuous subcutaneous levodopa/carbidopa infusion system for Parkinson’s disease motor fluctuations.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $150M
AI Company Overview
NeuroDerm creates a continuous subcutaneous levodopa/carbidopa infusion system for Parkinson’s disease motor fluctuations.
Neurology
Technology Platform
Proprietary liquid levodopa/carbidopa formulation delivered continuously via a subcutaneous infusion pump with integrated digital health monitoring.
Opportunities
Regulatory approval of ND0612 could capture a sizable share of the Parkinson’s disease infusion market and enable expansion into other CNS indications using the same drug‑device platform.
Risk Factors
Regulatory delays, reimbursement challenges, and competition from established oral and infusion therapies could impede market adoption.
Competitive Landscape
Key competitors include AbbVie’s Duodopa and other continuous dopaminergic delivery systems; NeuroDerm differentiates through a less invasive subcutaneous pump and integrated digital health monitoring.